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A B S T R A C T
Purpose
Higher doses of the anthracycline daunorubicin during induction therapy for acute myeloid leukemia
(AML) have been shown to improve remission rates and survival. We hypothesized that im-
provements in outcomes in adult AML may be further achieved by increased anthracycline dose
during consolidation therapy.
Patients and Methods
Patients with AML in complete remission after induction therapywere randomly assigned to receive
two cycles of consolidation therapy with cytarabine 100mg/m2 daily for 5 days, etoposide 75mg/m2
daily for 5 days, and idarubicin 9 mg/m2 daily for either 2 or 3 days (standard and intensive arms,
respectively). The primary end point was leukemia-free survival (LFS).
Results
Two hundred ninety-three patients 16 to 60 years of age, excluding those with core binding factor
AML and acute promyelocytic leukemia, were randomly assigned to treatment groups (146 to the
standard arm and 147 to the intensive arm). Both groups were balanced for age, karyotypic risk, and
FLT3– internal tandem duplication and NPM1 gene mutations. One hundred twenty patients in the
standard arm (82%) and 95 patients in the intensive arm (65%) completed planned consolidation
(P , .001). Durations of severe neutropenia and thrombocytopenia were prolonged in the intensive
arm, but there were no differences in serious nonhematological toxicities. With a median follow-up
of 5.3 years (range, 0.6 to 9.9 years), there was a statistically signiﬁcant improvement in LFS in the
intensive arm comparedwith the standard arm (3-year LFS, 47% [95%CI, 40% to 56%] v 35% [95%
CI, 28% to 44%]; P = .045). At 5 years, the overall survival rate was 57% in the intensive arm and
47% in the standard arm (P = .092). There was no evidence of selective beneﬁt of intensive
consolidation within the cytogenetic or FLT3– internal tandem duplication and NPM1 gene mutation
subgroups.
Conclusion
An increased cumulative dose of idarubicin during consolidation therapy for adult AML resulted in
improved LFS, without increased nonhematologic toxicity.
J Clin Oncol 35:1678-1685. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Anthracyclines are one of the major classes of
drugs active against acute myeloid leukemia
(AML).1 Daunorubicin used at 45 mg/m2 daily for
3 days is an integral component of the 7 + 3
regimen, which, with various modiﬁcations, has
been the standard induction regimen for AML for
more than three decades.2 Increased daunorubicin
dosage from 45 to 50 mg/m2 to 90 mg/m2 daily for
3 days during induction therapy for AML has been
shown in three studies to improve remission rates
and survival in some patient subgroups, although
another trial showed no beneﬁt of 90 mg/m2
compared with 60 mg/m2, with the caveat that the
lower-dose arm received a median cumulative total
of 330 mg/m2 daunorubicin.3-7 Another anthra-
cycline widely used for AML induction is idar-
ubicin. Several randomized trials have now been
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conducted comparing idarubicin 12 mg/m2 daily for 3 days with
daunorubicin 45 to 50 mg/m2 in the same schedule, with most
showing superiority for idarubicin,8-13 but the two anthracyclines
may not have been used at equipotent doses. This hypothesis is
supported by two recent studies comparing idarubicin at the 12 mg/
m2 dose for 3 days with daunorubicin 50 mg/m2 for 5 days, or
daunorubicin 80 mg/m2 for 3 days, which showed no differences in
outcome,14,15 suggesting that idarubicin 12 mg/m2 may be thera-
peutically equivalent to higher doses of daunorubicin. The ALFA-
9801 study also contained a high-dose idarubicin arm (12 mg/m2/
day 3 four doses), which resulted in a higher rate of complete
remission than the other two arms, but no difference in survival.15
Collectively, these studies suggest a beneﬁt for more intensive
anthracycline application during AML induction therapy, either by
higher daunorubicin doses than traditionally used, or by the use of
idarubicin.
Improved long-term outcomes in AML have also been
achieved by dose intensiﬁcation of antileukemic therapy during
consolidation treatment. The survival beneﬁt of dose escalation of
cytarabine, the other major drug used for treatment of AML, was
established in a landmark study by the Cancer and Leukemia Group
B, although this beneﬁt was predominantly seen in cases with core
binding factor rearrangements.16 The ﬁndings of this study have
recently been challenged by other trials, in particular the JALSG-
AML201 trial, which showed equivalent outcomes for three cycles of
high-dose cytarabine compared with four cycles of multiagent
consolidation chemotherapy.17 Although the precise dose and
scheduling of cytarabine in consolidation required for improvement
in survival remains controversial, one or more cycles of in-
termediate- to high-dose cytarabine have been recommended
and are widely used.18,19 In contrast, the intensity of anthra-
cycline therapy during consolidation has not been explored, to
our knowledge. Indeed, although attenuated doses of dauno-
rubicin were given as consolidation in the original 7 + 3
regimen, most protocols using high-dose cytarabine consoli-
dation do not incorporate anthracyclines. Therefore, there may
be an opportunity to explore higher anthracycline doses in
consolidation therapy, particularly when high-dose cytarabine
is not used.
The Australasian Leukaemia & Lymphoma Group (ALLG) has
previously explored the use of high doses of cytarabine during
induction therapy.20,21 In the ALLG M7 trial, the combination of
idarubicin at the standard 12mg/m2 dose for 3 days with high-dose
cytarabine and etoposide resulted in excessive severe GI toxicity,
deﬁning an upper tolerability boundary for induction in-
tensiﬁcation, and a reduction of idarubicin dose to 9 mg/m2 for
3 days was necessary.22 To further improve outcomes in adult AML
by anthracycline dose escalation, the ALLG conducted a phase III
trial examining the impact on outcome of increased idarubicin
dose intensity during consolidation therapy after high-dose
cytarabine–based induction.
PATIENTS AND METHODS
Patient Eligibility and Recruitment
This randomized phase III clinical trial, designated ALLG M12, was
registered with the Australian and New Zealand Clinical Trials Register
(ANZCTR number 12605000095662) and was conducted in 23 Australian
hospitals afﬁliated with the ALLG between July 2003 and April 2010. The
study was conducted according to the Declaration of Helsinki, and
monitored by an independent Safety and Data Monitoring Committee.
The study protocol was approved by the Human Ethics Committee of each
participating hospital. All patients gave written informed consent before
enrollment, ie, at the time of diagnosis before the start of induction
therapy. Eligible patients had a recent diagnosis of untreated AML (ex-
cluding cases with chromosomal rearrangements involving core binding
factor or acute promyelocytic leukemia, which were treated on separate
protocols), were 15 to 60 years of age, had an Eastern Cooperative On-
cology Group (ECOG) performance status score of 0 to 3, had absence of
serious organ dysfunction, and had no history of other cancer. For eli-
gibility to be randomly assigned to treatment in the consolidation trial,
patients were required to be in complete remission (CR) after one or two
cycles of induction therapy, with unsupported absolute neutrophil count
$ 1.0 3 109/L and platelet count $ 100 3 109/L; to have no active in-
fection; to have an ECOG performance status score of 0 to 2; and to have no
major renal, cardiac, hepatic, or neurotoxicity. A protocol amendment in
2005 allowed random assignment of patients at diagnosis to receive
palifermin as a mucosal protectant or placebo during induction therapy,
the results of which have been published separately.23
Protocol Therapy and Study Conduct
The induction protocol was based on previous ALLG studies in
induction, which explored high-dose cytarabine and deﬁned the maximal
tolerated dose of idarubicin in combination with high-dose cytarabine and
etoposide as 9 mg/m2 for 3 days.20-22 Patients with previously untreated
AML achieving CR after one to two cycles of intensive induction therapy
(idarubicin 9 mg/m2 daily for 3 days; cytarabine 3 g/m2 twice daily on days
1, 3, 5, and 7; and etoposide 75 mg/m2 daily for 7 days; ICE protocol21,22)
were randomly assigned to receive two cycles of consolidation therapy with
cytarabine 100mg/m2 daily for 5 days, etoposide 75mg/m2 daily for 5 days,
and idarubicin 9 mg/m2 daily for either 2 or 3 days (standard and intensive
arms, respectively). The intensive arm initially contained four dosages of
idarubicin, but this produced unacceptable myelotoxicity and was
amended to three dosages in January 2004 after 15 patients had been
randomly assigned. Supportive care during consolidation included peg-
ﬁlgrastim 6 mg subcutaneously on day 6 after each course, as well as
antifungal prophylaxis and other therapy according to institutional
standards. No further protocol therapy was given.
Cytogenetic and Gene Mutation Analysis
Cytogenetic analysis of diagnostic bone marrow biopsy samples was
performed using standard metaphase-banding techniques in accredited
diagnostic laboratories associated with individual participating hospitals,
and classiﬁed according to published criteria.24 All karyotypes were
reviewed centrally by an experienced cytogeneticist (L.C.).
Molecular testing for mutations in the FLT3 and NPM1 genes was
done using DNA extracted from leukemic cells obtained at diagnosis in two
reference laboratories, using published methods.25,26
Statistical Methods
The speciﬁed primary end point was 3-year leukemia-free survival
(LFS) from the time of random assignment to consolidation therapy in ﬁrst
CR to the date of relapse (International Working Group Criteria)27 or
death in remission, on the basis of intention to treat among eligible pa-
tients. Secondary end points were 3-year overall survival, toxicity of
consolidation therapy, and effects of therapy on minimal residual disease,
on the basis of WT1 expression levels (to be reported separately). The
close-out date for the analysis was July 31, 2013. The planned total sample
size was 288 patients randomly assigned to receive consolidation therapy,
which provides a power of 80% to detect an increase in 3-year LFS from
50% to 67% with a P value of .05. Differences in LFS and overall survival
jco.org © 2017 by American Society of Clinical Oncology 1679
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between treatment groups were assessed by Kaplan-Meier estimates for
rates at 3 years, and Fisher’s exact tests were used for toxicity rates andWT1
expression levels. The association of baseline characteristics with LFS was
assessed using Cox proportional hazards regression, with the best multiple
variables selected using backward elimination, adding all possible in-
dependent variables and removing those with the smallest x2 value from
type III sum of squares until all terms in the model were signiﬁcant
predictors. In exploratory analyses, the treatment effect was assessed within
particular subgroups by considering the interaction term P value.
RESULTS
Patient Characteristics
A total of 422 patients with AML, who were 16 to 60 years of
age, was enrolled between 2003 and 2010, with 345 (82%)
achieving CR; 93% of these patients achieved CR with one ICE
(idarubicin 9 mg/m2 daily for 3 days; cytarabine 3 g/m2 twice daily
on days 1, 3, 5, and 7; and etoposide 75 mg/m2 daily for 7 days; ICE
protocol21,22) course (Fig 1). Of these, 293 patients were randomly
assigned to the standard (n = 146) or intensive (n = 147) con-
solidation arms, whereas 52 patients were not randomly assigned,
as the result of induction toxicity (n = 36), bone marrow trans-
plantation (BMT; n = 11), relapse (n = 2), ECOG performance
status score . 2 (n = 1), withdrawal of consent (n = 1), and death
(n = 1). The median age of randomly assigned patients was 45 years
in both arms (range, 16 to 60 years), and groups were balanced for
sex, karyotypic risk,25 and frequency of mutations involving the
FLT3-ITD and NPM1 genes (Table 1). Overall, 12% of randomly
assigned patients had an adverse karyotype. Ninety-six (42%) of
229 patients tested for NPM1 mutations had positive results, and
73 (32%) of 230 patients tested for FLT3-ITD mutations had
positive results.
Treatment Delivery
Of the 293 randomly assigned patients, 120 in the standard
arm (82%) and 95 in the intensive arm (66%) completed both
planned consolidation cycles (P, .001; Appendix Table A1, online
only). If the second consolidation cycle was not commenced, it was
mainly because of greater toxicity from the ﬁrst cycle in the in-
tensive arm (28 patients; 19%) compared with 13 (9%) patients in
the standard arm. Additional factors for not completing protocol
treatment were disease relapse (ﬁve patients in the standard arm
and four patients in the intensive arm), delivery of allogeneic BMT
(seven patients in the standard arm and 11 patients in the intensive
arm), and other reasons (one patient in the standard arm and ﬁve
patients in the intensive arm). The median total dose of idarubicin
received in the two consolidation courses was 36 mg/m2 (range,
17 to 45 mg/m2), or 99% (range, 47% to 125%) of the protocol
dose, in the standard arm versus 53 mg/m2 (range, 18 to 73 mg/m2),
or 98% (range, 33% to 136%) of the protocol dose, in the intensive
arm (Appendix Table A2, online only).
Forty and 38 patients in the standard and intensive groups,
respectively, underwent elective allogeneic BMT in ﬁrst CR (CR1).
Discontinued intervention
Lost to follow-up
BMT in CR1
BMT after relapse
(n = 26)
(n = 13)
(n = 40)
(n = 48)
Discontinued intervention
Lost to follow-up
BMT in CR1
BMT after relapse
(n = 51)
(n = 13)
(n = 38)
(n = 38)
Registered in study
(n = 442) 
Follow-Up
Randomly allocated
(n = 296) 
Enrollment
Excluded
 No CR in induction cycles
Eligible
Ineligible
(n = 76)
(n = 15)
 Had CR in induction cycles, but
    did not proceed to
    consolidation therapy
Eligible
Ineligible
(n = 53)
(n = 2)
Allocated to standard arm (n = 147)
    Ineligible
    Received allocated intervention
    Did not receive allocated
      intervention
(n = 1)
(n = 146)
(n = 0)
    Ineligible
    Received allocated intervention
    Did not receive allocated
      intervention
(n = 2)
(n = 145)
(n = 2)
Allocated to intensive (n = 149)
Analyzed
Excluded from analysis
(n = 146)
(n = 1 ineligible)
Analyzed
Excluded from analysis
(n = 147)
(n = 2 ineligible)
Analysis
Allocation
Fig 1. CONSORT diagram for AMLM12.
BMT, bone marrow transplantation; CR,
complete remission.
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Toxicity of Consolidation Therapy
The duration of grade 3 to 4 neutropenia was signiﬁcantly
longer in the intensive arm in both course one (median, 10 v
6 days; P , .001) and course 2 (median, 12 v 9 days; P , .001)
as was grade 3 to 4 thrombocytopenia in course one (median,
20 v 14 days; P , .001) and course 2 (median, 21 v 15 days;
P = .01; Table 2). There were no differences in the rates of
neutropenic fever, clinically or microbiologically proven in-
fection, or grade 3 or 4 nonhematological toxicities between
the arms. There were no deaths during consolidation in the
standard arm and there were two deaths in the intensive arm
(0% v 1%; P = .50).
Disease Relapse and Death
Of the randomly assigned patients, 93 (64%) in the standard
arm and 74 (50%) in the intensive arm suffered leukemic relapse,
with 83 and 67 of these, respectively, occurring in bone marrow
and the remainder in extramedullary sites. Following relapse, 48
(33%) of patients in the standard arm and 38 (26%) of patients in
the intensive arm underwent salvage BMT. Seventy-eight pa-
tients in the standard arm and 63 patients in the intensive arm
died, predominantly after disease relapse (61 and 49 cases,
respectively) or after allogeneic BMT in CR1 (15 and 12 cases,
respectively). After censoring patients who received elective
allogeneic BMT in CR1 at the time of transplant, the time to
relapse was signiﬁcantly longer in the intensive arm compared
with the standard arm (median time to relapse, 17 v 10 months,
respectively; P = .017; Fig 2A).
Survival Outcomes
With a median follow-up of 5.3 years (range, 0.6 to 9.9 years),
there was a statistically signiﬁcant improvement in LFS in the
intensive arm compared with the standard arm (3-year LFS, 47%
[95% CI, 40% to 56%] v 35% [95% CI, 28% to 44%]; HR for
intensive arm, 0.74 [95% CI, 0.55 to 0.99]; P = .045; Fig 2B). The
estimated median LFS was 0.93 years (95% CI, 0.80 to 1.49) in the
standard arm versus 2.13 years (95% CI, 1.07 to . 9.0) in the
intensive arm. In a post hoc analysis, when the 78 patients (40 in
the standard arm and 38 in the intensive arm) who underwent
elective allogeneic BMT in CR1 were censored at the time of
transplant, the difference in 3-year LFS between the intensive and
standard arms was still evident (3-year LFS, 43% [95% CI, 35% to
44%] v 27% [95% CI, 19% to 37%]; HR for intensive arm, 0.68
[95% CI, 0.49 to 0.93]; P = .017; Fig 2C). There was, however, no
difference in 3-year LFS between the arms in patients who had
BMT in CR1 (P = .94). Three-year overall survival was 61% (95%
CI, 54% to 70%) for the intensive arm versus 50% (95%CI, 43% to
59%) for the standard arm; HR for intensive arm, 0.75 (95% CI,
0.54 to 1.05; P = .092; Fig 2D). Overall survival following relapse
was comparable between the arms; following relapse, the median
overall survival was 243 days (range, 182 to 331 days) in the
standard arm and 268 days (range, 183 to 473 days) in the intensive
arm (P = .60).
To examine whether early withdrawal from the study was
detrimental, an exploratory landmark survival analysis was
conducted. Patients randomly assigned to the intensive arm
who received only one consolidation course did not seem to
have an inferior outcome compared with those completing two
courses (estimated 3-year LFS, 69% [range, 55% to 87%] for
one course v 44% [range, 35% to 55%] for two courses), while
seeming to have a better outcome than those who received only
one standard consolidation course (estimated 3-year LFS 29%
[range, 12% to 65%]; Appendix Fig A1, online only).
Analysis of Factors Predictive of LFS
In univariable analysis, treatment in the standard arm, adverse
karyotypic risk, and absence of NPM1 mutation were associated
with inferior LFS (Table 3). Patient age, however, was not a pre-
dictive factor. Within the group of patients without adverse risk
cytogenetics, the presence of FLT3-ITD was also associated with
inferior LFS compared with the presence of NPM1 mutation. In
multivariable analysis, the treatment arm and the presence of
FLT3-ITD or NPM1 mutations were all signiﬁcant predictive
factors. In an exploratory analysis, however, there was no evidence
Table 2. Duration of Neutropenia and Thrombocytopenia
Type of Cytopenia
No. of
Patients
Median Days to
Recovery (95% CI)
x2 PStandard Intensive
Neutropenia,
course 1
289 6 (5 to 6) 10 (8 to 11) 27.7 , .001
Neutropenia,
course 2
215 9 (8 to 9) 12 (10 to 13) 20.3 , .001
Low platelets,
course 1
289 14 (11 to 16) 20 (17 to 23) 19.3 , .001
Low platelets,
course 2
215 15 (13 to 18) 21 (17 to 23) 6.3 .01
NOTE. Neutropenia, days with absolute neutrophil count # 0.5 3 109/L;
thrombocytopenia, days with platelet count # 20 3 109/L.
Table 1. Characteristics of Randomly Assigned Patients
Characteristic Standard Arm Intensive Arm P
No. of patients 146 147
Sex, No. of patients (%) .38
Male 78 (53) 86 (59)
Female 68 (47) 61 (41)
Age in years, mean 45.3 44.9 .78
Standard deviation 11.5 11.6
No. of induction courses (%) .60
1 137 (94) 140 (95)
2 9 (6) 7 (5)
Cytogenetics, No. of patients (%)
Intermediate 118 (81) 122 (83)
Adverse 20 (14) 16 (11)
Not done 8 (5) 9 (6)
NPM1 mutation, No. of patients (%) .48
Detected 46 (32) 50 (34)
Not detected 70 (48) 63 (43)
Not done 30 (21) 34 (23)
FLT3-ITD, No. of patients (%) .47
Detected 40 (27) 33 (22)
Not detected 78 (53) 79 (54)
Not done 28 (19) 35 (24)
Abbreviation: ITD, internal tandem duplication.
jco.org © 2017 by American Society of Clinical Oncology 1681
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of a selective (or preferential) beneﬁt of intensive consolidation
therapy within speciﬁc cytogenetic or gene mutation subgroups
(Table 4; Appendix Figs A2 and A3, online only).
DISCUSSION
This randomized trial in adult AML showed improved LFS for
the cohort of patients who received the 50% increased dose of
idarubicin during consolidation therapy. To our knowledge, this
is the ﬁrst such study to examine the value of postremission
anthracycline dose escalation in consolidation therapy for AML.
One advantage of using the strategy of escalation of antileu-
kemic therapy during the consolidation phase of treatment is
that patients are usually in better medical condition, with
resolution of disease-related problems such as infection and
organ dysfunction that are often present at diagnosis, and
normalization of cytopenia. Anthracyclines are notable for GI
mucosal toxicities, and exacerbation of mucositis by anthra-
cyclines during induction therapy may contribute to treatment-
related complications that limit efﬁcacy; indeed, higher mor-
tality as a result of toxicity led to premature closure of the high-
dose daunorubicin arm in a recent randomized trial.6 Hence,
the consolidation phase of treatment may offer a more suitable
setting for testing the value of increased idarubicin dose. No-
tably, we did not observe any difference in the incidence of
serious nonhematological toxicities between the arms, nor
a signiﬁcant difference in the incidence of treatment-related
deaths, despite a clear increase in myelotoxicity in the intensive
arm, which provided a pharmacodynamic indicator of dose
intensity.
Another potential adverse effect of anthracycline therapy is
cardiotoxicity, both in the acute setting and also as long-term
cardiomyopathy. We did not observe an increase in any serious
cardiac adverse events in the intensive arm during the follow up
period, although it remains possible that cardiomyopathy may
emerge as a complication in some patients with prolonged
follow-up. Increased cardiotoxicity has not emerged thus far in
any of the trials using daunorubicin dose escalation during
induction therapy.2-5
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Increased myelotoxicity was observed in the intensive arm and
was the predominant reason for the higher rate of withdrawal from
the trial after one cycle of intensive consolidation compared with
standard treatment. We speculate that the myelotoxicity observed
in the intensive arm was also reﬂected in greater antileukemic
activity, resulting in a lower relapse rate than the standard arm.
This is supported by the ﬁnding that patients in the intensive arm
who only received one cycle of consolidation therapy did not seem
to have a worse outcome than those who completed both courses.
Dose-escalation strategies following remission induction, in-
cluding high-dose cytarabine (following the landmark Cancer and
Leukemia Group B trial), alternating multiagent chemotherapy
cycles, and autologous or allogeneic BMT, have been widely used to
reduce leukemic relapse rates and to improve long-term survival in
AML.16,28-31 This study adds to the options available for increasing
treatment intensity in consolidation therapy.
In exploratory analyses, we could not detect a speciﬁc beneﬁt
of increased idarubicin dose in any patient subgroups (in par-
ticular, younger v older ages, adverse v intermediate karyotypes,
and mutations in the FLT3 and NPM1 genes), although the low
numbers of cases in some subgroups limited the power to do so.
Other studies of anthracycline dose escalation during induction
therapy have shown conﬂicting results. In the updated ECOG
E1900 study, patients younger than 50 years; those with favorable
or intermediate karyotypes; or those with FLT3-ITD, DNMT3A, or
NPM1 gene mutations all beneﬁted from an increased daunoru-
bicin dose in induction; in multivariable analysis, adverse kar-
yotype and ages 50 to 60 years with FLT3-ITD or NPM1 mutation
also beneﬁted from increased daunorubicin dose.3 In contrast, in
the HOVON/SAKK study, which was restricted to patients 60 years
and older, a beneﬁt of higher daunorubicin dose was only evident
in those 60 to 65 years of age.4 In a large Korean study comparing
45 versus 90 mg/m2 doses of daunorubicin in induction, the
beneﬁts of high-dose daunorubicin were observed in patients
younger than 40 years of age and in those with intermediate-risk
karyotypes.5
Although there was a trend to improved survival, we were
unable to demonstrate a signiﬁcant improvement in overall sur-
vival in the intensive arm compared with the standard arm,
possibly as a result of the relatively high proportion of patients
undergoing elective allogeneic BMT in ﬁrst remission or as salvage
therapy following relapse, but it also must be recognized that the
study was powered for LFS and not for overall survival.
We conclude that an increased dose intensity of idarubicin
during consolidation therapy for adult AML results in improved
LFS, without increased nonhematologic toxicity, and represents
a reasonable strategy to explore to further improve outcomes for
this disease.
Table 3. Predictors of Leukemia-Free Survival From Consolidation Random Assignment Among Patients in AMLM12: Univariable Analyses
Parameter Hazard Ratio Interpretation No.
Hazard Ratio
x2 DF Pr . x2Estimate
95% CI
Lower Upper
Arm Intensive v standard 293 0.74 0.55 0.99 4.0 1 0.05
Age_SD Per 1 SD age in years 293 1.00 0.85 1.16 0.0 1 0.95
Sex Female v male 293 0.94 0.70 1.27 0.2 1 0.70
MRC classiﬁcation Adverse v intermediate 276 1.59 1.05 2.42 4.3 1 0.04
FLT3 (ITD) Detected v not 230 1.36 0.97 1.90 3.0 1 0.08
NPM1 (W288C) Mutated v wild-type 229 0.64 0.46 0.90 6.8 1 0.009
Cytogenetic, mutation group Not adverse cytogenetics, FLT3-ITD detected, no NPM1
detected
293 1.54 0.91 2.60 14.6 5 0.01
Adverse cytogenetics 1.41 0.87 2.27
Not adverse cytogenetics, FLT3-ITD and NPM1 mutations
detected
1.05 0.65 1.70
Not adverse, no FLT3-ITD or NPM1 mutations detected 1.00
Other (unknown FLT3, NPM1, cytogenetics) 0.78 0.51 1.20
Not adverse cytogenetics, NPM1 detected, no FLT3-ITD
detected
0.62 0.38 1.01
NOTE. The list of variables that were assessed for prediction of leukemia-free survival is provided in the Appendix (online only).
Abbreviations: ITD, internal tandem duplication; MRC, Medical Research Council.
Table 4. Multivariable Model: Baseline Predictors of Leukemia-Free Survival From Consolidation Randomization
Parameter
Hazard Ratio
Interpretation
No. of
Observations Used
Hazard Ratio for
Relapse or Death 95% CI, Lower 95% CI, Upper x2 DF Pr . x2
Model ﬁt parameters 227 21.0 3 0.0001
Arm Intensive v standard 0.62 0.45 0.87
FLT3-ITD Detected v not detected 1.61 1.13 2.30
NPM1 mutation Detected v not detected 0.57 0.40 0.81
NOTE. Selected from 30 baseline characteristics in a backward-selection model determined such that remaining individual terms in model have P , .05.
Abbreviation: ITD, internal tandem duplication.
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Appendix
Statistical Methods
All tests were two-sided and were considered to be signiﬁcant if P # .05. All statistical analyses were performed using SAS
version 9.3 (SAS Institute Inc, Cary, NC), with ﬁgures plotted in R (version 3.2.4).
The list of variables that were assessed for prediction of leukemia-free survival (LFS) included consolidation treatment arm,
number of induction courses, age (continuous), induction study status (randomly assigned to palifermin v placebo v not randomly
assigned v recruited before this study), sex, height (continuous), weight (continuous), French-American-British classiﬁcation
(seven groups andM1 v not M1), Eastern Cooperative Oncology Group (three groups: 0, 1, 2/3), study entry (neutrophils, platelets,
blasts [continuous]), bleeding status (catastrophic, mild, none [as three groups or two groups]), febrile (yes/no), bone marrow
blasts, bonemarrow cellularity (hypocellular, hypercellular, or normocellular), FLT3 (internal tandem duplication) mutation status,
NPM1 (W288C) mutation status, cytogenetics (abnormal v normal and Medical Research Council classiﬁcation of adverse v
intermediate), mutation group (adverse cytogenetics v not adverse cytogenetics and no mutations at FLT3 or NPM1, mutation at
FLT3 only, mutation at NPM1 only, mutations at both FLT3 and NPM1, unknown status), WT1 in bone marrow and peripheral
blood at pretreatment and at end of induction (four continuous variables on log scale, and detected v not detected with threshold of
250 copies/104 ABL in bone marrow and 10 copies/104 ABL in peripheral blood), days from diagnosis to random assignment
(continuous), days from registration to complete response during induction therapy (continuous), days from complete response to
random assignment (continuous), days from registration to random assignment (continuous).
Results
Time to random assignment. The median time from study registration to conﬁrmation of complete response was 31 days, and
the median time from complete response to random assignment was 4 days.
Overall survival of patients registered in M12 trial. Themedian overall survival for all patients registered in the trial was 3.6 years
(95% CI, 2.50 to 6.67; Appendix Fig A4, online only).
Impact of random assignment to palifermin on consolidation trial. Overall, 17% and 19% of patients in the standard arm, and
20% and 20% of patients in the intensive arm, were randomly assigned to palifermin or placebo, respectively (Appendix Table A3,
online only).
There was no signiﬁcant difference in any grade 3 or 4 toxicities in the two randomization arms according to whether patients
received palifermin or placebo (Appendix Table A4, online only).
Random assignment to receive palifermin randomization was not a predictive factor for LFS or overall survival, nor the
effectiveness of intensive versus standard treatment of LFS or overall survival (Appendix Tables A5 and A6, online only).
Impact of WT1minimal residual disease levels on consolidation trial. Minimal residual disease (MRD) levels after induction were
comparable between the randomization arms (Appendix Table A7, online only).
There was no evidence that the beneﬁt among patients withMRD in peripheral blood at the end of inductionwas different than
those patients without MRD (Appendix Fig A3, online only).
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Survival following relapse. Following relapse, the median overall survival was 243 days (95% CI, 182 to 331 days) in the
standard arm and 268 days (95% CI, 183 to 473 days) in the intensive arm (P = .60; Appendix Fig A5, online only).
LFS for patients undergoing bone marrow transplantation in ﬁrst complete remission. There was no difference in 3-year LFS
between the arms in patients who had bone marrow transplantation in ﬁrst complete remission (P = .94; Appendix Fig A6, online
only).
Table A2. Percentage of Protocol Doses of Idarubicin Delivered During Consolidation
Variable
Standard Arm Intensive Arm
Consolidation 1 Consolidation 2 Consolidation 1 Consolidation 2
No. of patients 146 120 145 95
Median dose delivered, % 100 100 100 100
Range of dose delivered, % 50-139 74-139 33-137 33-107
Patients receiving 90%-110% of protocol dose, No. (%) 141 (97) 118 (98) 140 (97) 87 (92)
Table A1. Reasons Why Randomly Assigned Patients Did Not Start Consolidation Course 2
Reason
Standard Arm,
No. of Patients
Standard Arm, % of Patients
Starting First Course
Intensive Arm,
No. of Patients
Intensive Arm, % of Patients
Starting First Course
Relapse 5 3 4 3
BMT 7 5 11 8
Unacceptable toxicity 13 9 28 19
Patient refusal 0 0 1 1
Death 0 0 2 1
Other 1 1 4 3
Total 26 18 50 34
Abbreviation: BMT, bone marrow transplantation.
Table A3. Inﬂuence of Palifermin Randomization on Consolidation Arms
Random Assignment
Intensive Arm,
No. (%)
Standard Arm,
No. (%)
No. of patients 147 146
Allocated to receive placebo 30 (20) 28 (19)
Allocated to receive palifermin 30 (20) 25 (17)
Not randomly assigned 20 (14) 30 (21)
Recruited before palifermin amendment 67 (46) 63 (43)
NOTE.x2 test for differences: df 3, P = .45.
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Table A4. Inﬂuence of Palifermin Randomization on Toxicities in Consolidation
Adverse Event (grade $ 3)
Observed in
Consolidation
Study, No. (%)
Observed Among Patients
Randomly Assigned to
Receive Palifermin, No. (%)
Observed Among Patients
Randomly Assigned to
Receive Placebo, No. (%)
Observed Among
Others, No. (%)
x2 Test for
Differences
No. of adverse events 293 55 58 180
Catheter-related infection 27 (9.2) 5 (9.1) 2 (3.4) 20 (11.1) 0.69
Diarrhea in patients without colostomy 14 (4.8) 0 (0.0) 3 (5.2) 11 (6.1) 0.63
Febrile neutropenia 107 (36.5) 18 (32.7) 20 (34.5) 69 (38.3) 0.98
Hemoglobin 14 (4.8) 4 (7.3) 0 (0.0) 10 (5.6) 0.56
Hemorrhage/bleeding with grade 3 to 4
thrombocytopenia
28 (9.6) 3 (5.5) 3 (5.2) 22 (12.2) 0.57
Hypotension 25 (8.5) 1 (1.8) 4 (6.9) 20 (11.1) 0.43
Infection documented clinically or
microbiologically with grade 3 to 4
neutropenia
187 (63.8) 31 (56.4) 36 (62.1) 120 (66.7) 0.84
Infection without neutropenia 27 (9.2) 5 (9.1) 3 (5.2) 19 (10.6) 0.91
Leukocytes 11 (3.8) 2 (3.6) 0 (0.0) 9 (5.0) 0.69
Lymphopenia 10 (3.4) 2 (3.6) 0 (0.0) 8 (4.4) 0.76
Nausea 14 (4.8) 2 (3.6) 0 (0.0) 12 (6.7) 0.48
Neutrophils/granulocytes (ANC/AGC) 30 (10.2) 3 (5.5) 4 (6.9) 23 (12.8) 0.65
Platelets 35 (11.9) 6 (10.9) 3 (5.2) 26 (14.4) 0.60
Stomatitis/pharyngitis (oral/pharyngeal
mucositis)
6 (2.0) 0 (0.0) 1 (1.7) 5 (2.8) 0.89
Vomiting 5 (1.7) 0 (0.0) 0 (0.0) 5 (2.8) 0.67
Abbreviations: AGC, absolute granulocyte count; ANC, absolute neutrophil count.
Table A5. Impact of Palifermin Randomization on LFS; Hazard Ratios for LFS
Parameter
No. of
Observations
Used
Hazard
Ratio 95% CI, Lower 95% CI, Upper x2 DF Pr . x2
Randomly assigned to palifermin v placebo 113 0.85 0.53 1.37 0.4 1 0.51
Group
Allocated to receive placebo 293 1.00 0.7 3 0.86
Allocated to receive palifermin 0.86 0.53 1.37
Not randomly assigned 0.82 0.51 1.33
Recruited before palifermin study amendment 0.88 0.60 1.30
Abbreviation: LFS, leukemia-free survival.
Table A6. Impact of Palifermin Randomization on OS; Hazard Ratios for OS
Parameter
No. of
Observations
Used
Hazard
Ratio 95% CI, Lower 95% CI, Upper x2 DF Pr . x2
Randomly assigned to palifermin v placebo 113 1.31 0.76 2.25 1.0 1 0.33
Group
Allocated to receive placebo 293 1.00 1.0 3 0.80
Allocated to receive palifermin 1.30 0.76 2.23
Not randomly assigned 1.06 0.60 1.87
Recruited before palifermin study amendment 1.11 0.70 1.77
Abbreviation: OS, overall survival.
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Table A7. Impact of Post-Induction WT-1 Levels on Outcome
Variable Standard Arm Intensive Arm
Exact
Test P Variable t Test P
. 10 WT1 copies/104 ABL in peripheral blood at day 28
after induction cycle 1
10 of 78 (13%) 7 of 82 (9%) .45 Log WT1 copies/104 ABL in peripheral blood at day 28
after induction cycle 1
.36
. 250 WT1 copies/104 ABL in bone marrow at day 28
after induction cycle 1
6 of 75 (8%) 4 of 78 (5%) .53 LogWT1 copies/104 ABL in bonemarrow at day 28 after
induction cycle 1
.83
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Fig A1. Landmark analysis of leukemia-free survival according to the number of consolidation courses actually received. Day 67 after consolidation randomization was
taken as the landmark date, because this was the latest date that a patient withdrew from the trial after course 1 for toxicity reasons. Est., estimated; Int, intensive arm; NA,
not assessable; Std, standard arm.
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Fig A2. Leukemia-free survival from consolidation randomization in AMLM12. (A) Among all patients, by randomized arm and Medical Research Council prognostic
classiﬁcation group. (B) Among patients with adverse risk group or status unknownwith regard toNPM1 and FLT3– internal tandem duplication (ITD), by randomized arm. (C
and D) Among patients of intermediate-risk classiﬁcation, by randomized arm and mutation status. Adverse, adverse risk; Both, both NPM1 and FLT3-ITD positive; Est.,
estimated; FLT3-ITD, FLT3-ITD positive only; Int, intensive arm; Inter, intermediate risk or risk group not determined; Mut, mutated; NA, not assessable; Neither, neither
NPM1 nor FLT3-ITD positive; NPM1, NPM1 positive only; Std, standard arm.
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Fig A3. Forest plot for leukemia-free survival for patient subgroups according to consolidation randomization arm; effect of consolidation treatment according to
subgroups on the basis of age, palifermin study status, cytogenetic risk group, FLT3 and NPM1 gene mutations, and WT1 minimal residual disease (MRD) levels.
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Fig A4. Overall survival of all patients registered in the M12 trial. Est., estimated.
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Fig A5. Survival of patients in the two arms following relapse. Est., estimated.
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Fig A6. Leukemia-free survival by randomization arm for patients undergoing allogeneic bone marrow transplantation in ﬁrst remission. Est., estimated.
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